Literature DB >> 3732369

Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults.

S J Szefler, W F Ebling, J W Georgitis, W J Jusko.   

Abstract

The disposition and plasma binding of methylprednisolone were examined in seven normal volunteers following the administration of 5, 20 and 40 mg of intravenous methylprednisolone sodium succinate. Methylprednisolone exhibits linear plasma protein binding averaging 77%. The mean plasma methylprednisolone clearance of 337 ml X h-1 X kg-1 was independent of dose. The steroid appears to moderately distribute into tissue spaces with a mean volume of distribution of 1.41 X kg-1. Methylprednisolone disposition parameters were compared with the non-transcortin bound parameters for prednisolone. The prednisolone plasma clearance based on the transcortin free-drug is similar to methylprednisolone total plasma clearance. However, the corrected volume of distribution of prednisolone is only one-half that of methylprednisolone. The disposition rate of these two steroids is thus similar, in spite of their metabolic control by different enzymatic pathways and major influence of saturable transcortin binding on prednisolone elimination.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732369     DOI: 10.1007/bf00541537

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunogassays.

Authors:  A W Meikle; J A Weed; F H Tyler
Journal:  J Clin Endocrinol Metab       Date:  1975-10       Impact factor: 5.958

2.  Metabolism of 1-dehydrosteroids in man. II. Isolation of 20alpha- and 20beta-hydroxy metabolites.

Authors:  A VERMEULEN; E CASPE
Journal:  J Biol Chem       Date:  1959-09       Impact factor: 5.157

3.  Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects.

Authors:  M Kozower; L Veatch; M M Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

4.  Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration.

Authors:  D Pessayre; M Konstantinova-Mitcheva; V Descatoire; B Cobert; J C Wandscheer; R Level; G Feldmann; D Mansuy; J P Benhamou
Journal:  Biochem Pharmacol       Date:  1981-03-15       Impact factor: 5.858

5.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

6.  Methylprednisolone disposition in rabbits. Analysis, prodrug conversion, reversible metabolism, and comparison with man.

Authors:  W F Ebling; S J Szefler; W J Jusko
Journal:  Drug Metab Dispos       Date:  1985 May-Jun       Impact factor: 3.922

7.  Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability.

Authors:  M Davis; R Williams; J Chakraborty; J English; V Marks; G Ideo; S Tempini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

8.  Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate. Absence of effects of troleandomycin on ester hydrolysis.

Authors:  W F Ebling; S J Szefler; W J Jusko
Journal:  J Chromatogr       Date:  1984-02-10

9.  Prednisone and methylprednisolone disposition in the lung.

Authors:  A C Braude; A S Rebuck
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

10.  Prednisolone clearance at steady state in man.

Authors:  U F Legler; F J Frey; L Z Benet
Journal:  J Clin Endocrinol Metab       Date:  1982-10       Impact factor: 5.958

View more
  20 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses.

Authors:  H Möllmann; P Rohdewald; J Barth; C Möllmann; M Verho; H Derendorf
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

3.  The Effect of Therapeutic Plasma Exchange on COVID-19 Therapy.

Authors:  Cansu GÖncÜoĞlu; Fatma Nisa Balli; Aygin Bayraktar EkİncİoĞlu
Journal:  Turk J Pharm Sci       Date:  2020-10-30

Review 4.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

5.  Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.

Authors:  B Lebrun-Vignes; V C Archer; B Diquet; J C Levron; O Chosidow; A J Puech; D Warot
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 6.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response.

Authors:  P J Hayball; D G Cosh; M J Ahern; D W Schultz; P J Roberts-Thomson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm.

Authors:  L E Fisher; E A Ludwig; J A Wald; R R Sloan; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1992-06       Impact factor: 6.875

9.  Troleandomycin effects on methylprednisolone and methylprednisone interconversion and disposition in the rabbit.

Authors:  W F Ebling; S A Rich; S J Szefler; W J Jusko
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

10.  The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits.

Authors:  W F Ebling; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1986-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.